...
首页> 外文期刊>Biomaterials >Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity
【24h】

Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity

机译:基于带有疏水部分作为阿霉素载体的乙二醇壳聚糖的自组装纳米颗粒:体内生物分布和抗肿瘤活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Self-assembled nanoparticles, formed by polymeric amphiphiles, have been demonstrated to accumulate in solid tumors by the enhanced permeability and retention effect, following intravenous administration. In this study, hydrophobically modified glycol chitosans capable of forming nano-sized self-aggregates were prepared by chemical conjugation of fluorescein isothiocyanate or doxorubicin to the backbone of glycol chitosan. Biodistribution of self-aggregates (300 mu in diameter) was evaluated using tissues obtained from tumor-bearing mice, to which self-aggregates were systemically administered via the tail vein. Irrespective of the dose, a negligible quantity of self-aggregates was found in heart and lung, whereas a small amount (3.6-3.8% of dose) was detected in liver for 3 days after intravenous injection of self-aggregates. The distributed amount of self-aggregates gradually increased in tumor as blood circulation time increased. The concentration of self-aggregates in blood was as high as 14% of dose at 1 day after intravenous injection and was still higher than 8% even at 3 days. When self-aggregates loaded with doxorubicin were administered into the tumor-bearing mice via the tail vein, they exhibited lower toxicity than but comparable anti-tumor activity to free doxorubicin. These results revealed the promising potential of self-aggregates on the basis of glycol chitosan as a carrier for hydrophobic antitumor agents. (c) 2005 Elsevier Ltd. All rights reserved.
机译:已经证明,由聚合物两亲物形成的自组装纳米颗粒在静脉内给药后由于增强的渗透性和保留作用而在实体瘤中蓄积。在这项研究中,通过将异硫氰酸荧光素或阿霉素与乙二醇壳聚糖的骨架化学偶联,制备了能够形成纳米级自聚集体的疏水改性乙二醇壳聚糖。使用得自荷瘤小鼠的组织评估自聚集体(直径300微米)的生物分布,并通过尾静脉对自聚集体进行全身给药。无论剂量如何,在心脏和肺部发现的自聚集物数量都可以忽略不计,而静脉内注射自聚集物后3天,在肝脏中检测到少量自聚集物(占剂量的3.6-3.8%)。随着血液循环时间的增加,自聚集物的分布量在肿瘤中逐渐增加。静脉注射后1天,血液中自聚集物的浓度高达剂量的14%,甚至在3天时仍高于8%。当通过尾静脉将载有阿霉素的自聚集体给药于荷瘤小鼠时,它们的毒性要比游离阿霉素低,但具有与之相当的抗肿瘤活性。这些结果揭示了基于乙二醇壳聚糖作为疏水性抗肿瘤剂载体的自聚集体的潜在潜力。 (c)2005 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号